Cancer Genetics, Inc. is an emerging leader in DNA-based cancer diagnostics and services some of the most prestigious medical institutions in the world. Our tests target cancers that are difficult to diagnose and predict treatment outcomes. These cancers include hematological, urogenital and HPV-associated cancers. We also offer a comprehensive range of non-proprietary oncology-focused tests and laboratory services that provide critical genomic information to healthcare professionals as well as biopharma and biotech. We have established strong research collaborations with major cancer centers such as Memorial Sloan-Kettering, The Cleveland Clinic, Mayo Clinic and the National Cancer Institute. For further information, please see www.cancergenetics.com.
Latest Results: Q3 2015 Quarterly
Feb 10 2016 • Convene Conference Center, New York, NY
- Feb 8 2016 9:21 AM EST Cancer Genetics, Inc. to Present at Source Capital Group’s 2016 Disruptive Growth & Healthcare Conference
- Feb 5 2016 8:00 AM EST Cancer Genetics, Inc. Expands the Reach of Precision Medicine by Over 2.6 Million Individuals as it Signs a New Agreement With Blue Cross Blue Shield of Minnesota
- Jan 21 2016 8:00 AM EST Cancer Genetics Launches Comprehensive Immuno-Oncology Testing Portfolio For Use in Clinical Trials, Translational Research, and Therapy Selection for Patients
Cancer Genetics, Inc.
201 Route 17 North
Rutherford, NJ 07070
Life Science Advisors LLC